The Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Grasustek, intended for prophylaxis against neutropenia in adult patients treated with cytotoxic chemotherapy. The applicant for this medicinal product is Juta Pharma GmbH.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
